WO2005074969A3 - Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1) - Google Patents

Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1) Download PDF

Info

Publication number
WO2005074969A3
WO2005074969A3 PCT/EP2005/000680 EP2005000680W WO2005074969A3 WO 2005074969 A3 WO2005074969 A3 WO 2005074969A3 EP 2005000680 W EP2005000680 W EP 2005000680W WO 2005074969 A3 WO2005074969 A3 WO 2005074969A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
nr4a1
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/000680
Other languages
French (fr)
Other versions
WO2005074969A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005074969A2 publication Critical patent/WO2005074969A2/en
Publication of WO2005074969A3 publication Critical patent/WO2005074969A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The invention provides a human NR4A1 which is associated with the cardiovascular diseases, dermatological diseases, endocrine system and hormone disorders, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle-skeleton disorders, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrine system and hormone disorders, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle-skeleton disorders, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NR4A1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/000680 2004-02-07 2005-01-25 Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1) WO2005074969A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002759 2004-02-07
EP04002759.1 2004-02-07

Publications (2)

Publication Number Publication Date
WO2005074969A2 WO2005074969A2 (en) 2005-08-18
WO2005074969A3 true WO2005074969A3 (en) 2005-10-20

Family

ID=34833576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/000680 WO2005074969A2 (en) 2004-02-07 2005-01-25 Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)

Country Status (1)

Country Link
WO (1) WO2005074969A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200094070A1 (en) * 2017-04-25 2020-03-26 Theralase Biotech Inc. Method and apparatus for photoactivating nuclear receptors
EP4103216A1 (en) * 2019-08-29 2022-12-21 University of Cincinnati Treatment of pain by targeting nr4a1
WO2023192969A1 (en) * 2022-04-01 2023-10-05 The Children's Medical Center Corporation Method for treating clonal hematopoietic blood disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087923A1 (en) * 2000-05-12 2001-11-22 Baylor College Of Medicine Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
WO2003014745A2 (en) * 2001-08-06 2003-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying anti-inflammatory drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087923A1 (en) * 2000-05-12 2001-11-22 Baylor College Of Medicine Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
WO2003014745A2 (en) * 2001-08-06 2003-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying anti-inflammatory drugs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 23, no. 7, July 2000 (2000-07-01), pages 815 - 819 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 2000 (2000-07-01), KANG HYO-JIN ET AL: "Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells", XP002330611, Database accession no. PREV200000405381 *
LIU S ET AL: "Induction of apoptosis by TPA and VP-16 is through translocation of TR3", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 8, no. 3, 2002, pages 446 - 450, XP002330609 *
WILSON ANDREW J ET AL: "TR3/Nur77 in colon cancer cell apoptosis.", CANCER RESEARCH, vol. 63, no. 17, 1 September 2003 (2003-09-01), pages 5401 - 5407, XP002330608 *
WU QIAO ET AL: "Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells.", CARCINOGENESIS (OXFORD), vol. 23, no. 10, October 2002 (2002-10-01), pages 1583 - 1592, XP002330607 *
YE XIAO-FENG ET AL: "Distinct role and functional mode of TR3 and RARalpha in mediating ATRA-induced signalling pathway in breast and gastric cancer cells.", INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 36, no. 1, January 2004 (2004-01-01), pages 98 - 113, XP002330610 *

Also Published As

Publication number Publication date
WO2005074969A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005075990A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)
WO2006008003A3 (en) Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2004099781A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)
WO2005085865A3 (en) Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
WO2005040829A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
WO2006008009A3 (en) Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6)
WO2005059504A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor gpr34 (gpr34)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase